Lundbeck Plans To Rebuild R&D Pipeline Mean Likely Job Losses
130-160 Positions Could Go In R&D
Executive Summary
Lundbeck wants to rebuild its R&D pipeline of products to treat brain disorders after recent disappointments, a process that could lead to job losses among the research organization, and more emphasis on deal-making.
You may also be interested in...
Lundbeck's Vyepti Launch In US Disappoints In First Half
The coronavirus pandemic held back sales of Lundbeck’s newest product, Vyepti, in the US during the first half, but the company spent less than expected on SG&A because of COVID-19, and increased investments in marketing infrastructure and restructuring R&D.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.